Ashley Woodcock

Ashley Woodcock

Auto-generated profile, based on publicly available information

Ashley Woodcock

University of Manchester, Manchester, UK

Research Focus & Metrics

Academic Career Length

48Years (1979-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 May 1982 in BMJ
Verified
Journal Article
Closed access
PDF file
RBR J Butland
R J Butland
JPJ Pang
J Pang
EGE R Gross
E R Gross
AWA A Woodcock
A A Woodcock
DGD M Geddes
D M Geddes

1 November 2008 in Thorax
Verified
Journal Article
Open access
PDF file
JHJ Henderson
J Henderson
RGR Granell
R Granell
JHJ Heron
J Heron
ASA Sherriff
A Sherriff
ASA Simpson
A Simpson
JSJ A C Sterne
J A C Sterne
Background: Patterns of wheezing during early childhood may indicate differences in aetiology and prognosis of respiratory illnesses. Improved characterisation of wheezing phenotypes could lead to the identification of environmental influences on the development of asthma and airway diseases in predisposed individuals. Methods: Data collected on wheezing at seven time points from birth to 7 years from 6265 children in a longitudinal birth cohort (the ALSPAC study) were analysed. Latent class analysis was used to assign phenotypes based on patterns of wheezing. Measures of atopy, airway function (forced expiratory volume in 1 s (FEV1), mid forced expiratory flow (FEF25-75)) and bronchial responsiveness were made at 7–9 years of age. Results: Six phenotypes were identified. The strongest associations with atopy and airway responsiveness were found for intermediate onset (18 months) wheezing (OR for atopy 8.36, 95% CI 5.2 to 13.4; mean difference in dose response to methacholine 1.76, 95% CI 1.41 to 2.12 %FEV1 per μmol, compared with infrequent/never wheeze phenotype). Late onset wheezing (after 42 months) was also associated with atopy (OR 6.6, 95% CI 4.7 to 9.4) and airway responsiveness (mean difference 1.61, 95% CI 1.37 to 1.85 %FEV1 per μmol). Transient and prolonged early wheeze were not associated with atopy but were weakly associated with increased airway responsiveness and persistent wheeze had intermediate associations with these outcomes. Conclusions: The wheezing phenotypes most strongly associated with atopy and airway responsiveness were characterised by onset after age 18 months. This has potential implications for the timing of environmental influences on the initiation of atopic wheezing in early childhood.

1 May 2006 in Thorax
Verified
Journal Article
Open access
PDF file
CMC S Murray
C S Murray
GPG Poletti
G Poletti
TKT Kebadze
T Kebadze
JMJ Morris
J Morris
AWA Woodcock
A Woodcock
ACA Custovic
A Custovic
Background: Asthma exacerbation is the most common cause of hospital admission in children. A study was undertaken to investigate the importance of allergen exposure in sensitised individuals in combination with viral infections and other potentially modifiable risk factors precipitating asthma hospital admission in children. Methods: Eighty four children aged 3–17 years admitted to hospital over a 1 year period with an acute asthma exacerbation (AA) were matched for age and sex with two control groups: stable asthmatics (SA) and children admitted to hospital with non-respiratory conditions (IC). Risk factors were assessed by questionnaires and determination of allergen sensitisation, home allergen exposure, pollen exposure, and respiratory virus infection. Results: Several non-modifiable factors (atopy, duration of asthma) were associated with increased risk. Among the modifiable factors, pet ownership, housing characteristics, and parental smoking did not differ between the groups. Regular inhaled corticosteroid treatment was significantly less common in the AA group than in the SA group (OR 0.2, 95% CI 0.1 to 0.6; p = 0.002). A significantly higher proportion of the AA group were virus infected (44%) and sensitised and highly exposed to sensitising allergen (76%) compared with the SA (18% and 48%) and IC groups (17% and 28%; both p<0.001). In a multiple conditional logistic regression (AA v SA), allergen sensitisation and exposure or virus detection alone were no longer independently associated with hospital admission. However, the combination of virus detection and sensitisation with high allergen exposure substantially increased the risk of admission to hospital (OR 19.4, 95% CI 3.7 to 101.5, p<0.001). Conclusions: Natural virus infection and real life allergen exposure in allergic asthmatic children increase the risk of hospital admission. Strategies for preventing exacerbations will need to address these factors.

15 June 2003 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
JKJohan C. Kips
Johan C. Kips
BOBrian J. O'COnnor
Brian J. O'COnnor
SLStephen J. Langley
Stephen J. Langley
AWAshley Woodcock
Ashley Woodcock
HKHuib Kerstjens
Huib Kerstjens
RPRomain A. Pauwels
Romain A. Pauwels
Antagonizing the effect of interleukin (IL)-5 is a potential new treatment strategy in allergic disorders. We evaluated the safety, biological activity, and pharmacokinetics of SCH55700, a humanized anti-human IL-5 antibody, in subjects with severe persistent asthma treated with oral or high doses of inhaled steroids. In a double-blind, randomized, multicenter trial, a rising single dose of SCH55700 (0.03 mg/kg [n = 2], 0.1 mg/kg [n = 4], 0.3 mg/kg [n = 6], or 1.0 mg/kg [n = 12]) or placebo (n = 8) was administered intravenously. SCH55700 dose dependently reduced circulating eosinophil counts. At a dose of 1.0 mg/kg, the decrease remained significant up to Day 30 [(0.07 ± 0.01) × 109/L versus (0.23 ± 0.04) × 109/L at baseline] (mean ± SEM) (p = 0.05). After administration of SCH55700 at 0.3 and 1.0 mg/kg, a trend toward improvement in baseline FEV1 was observed, which reached significance 24 hours after the 0.3-mg/kg dose (p = 0.019 versus placebo). No significant changes occurred in other clinical indices of disease activity. Adverse events were not different between active treatment and placebo. We conclude that SCH55700 is a biologically active anti-human IL-5 antibody that can be safely used in severe steroid-treated asthma. Its therapeutic potential needs to be addressed in specifically designed efficacy trials.

1 January 2010 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
NNNicolaos Nicolaou
Nicolaos Nicolaou
MPMaryam Poorafshar
Maryam Poorafshar
CMClare Murray
Clare Murray
ASAngela Simpson
Angela Simpson
HWHenric Winell
Henric Winell
ACAdnan Custovic
Adnan Custovic

1 November 2001 in The Lancet
Verified
Journal Article
Closed access
SSSarah Scrivener
Sarah Scrivener
HYHaile Yemaneberhan
Haile Yemaneberhan
MZMehila Zebenigus
Mehila Zebenigus
DTDaniel Tilahun
Daniel Tilahun
SGSamuel Girma
Samuel Girma
JBJohn Britton
John Britton